Dihydroergotamine (mesylate)

Dihydroergotamine mesylate is an ergot alkaloid that can be used for the research of migraines[1][2][3].

Product Specifications

CAS Number

[6190-39-2]

UNSPSC

12352005

Hazard Statement

H312, H332

Target

5-HT Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Dihydroergotamine-mesylate.html

Purity

99.94

Solubility

DMSO : 50 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O[C@@]([C@@](CCC1)([H])N1C2=O)(O[C@](NC([C@@H](CN(C)[C@]3([H])C4)C[C@]3([H])C5=C6C4=CNC6=CC=C5)=O)(C)C7=O)N7[C@H]2CC8=CC=CC=C8.CS(=O)(O)=O

Molecular Formula

C34H41N5O8S

Molecular Weight

679.78

Precautions

H312, H332

References & Citations

[1]Colman, I., et al., Parenteral dihydroergotamine for acute migraine headache: a systematic review of the literature. Ann Emerg Med, 2005. 45 (4) : p. 393-401.|[2]Saper, J.R., et al., DHE in the pharmacotherapy of migraine: potential for a larger role. Headache, 2006. 46 Suppl 4: p. S212-20.|[3]Schaerlinger, B., et al., Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy. Br J Pharmacol, 2003. 140 (2) : p. 277-84.|[4]Chang SH, et al. Dihydroergotamine Tartrate Induces Lung Cancer Cell Death through Apoptosis and Mitophagy. Chemotherapy. 2016;61 (6) :304-12.|[5]He M, et al. Dihydroergotamine mesylate enhances the anti-tumor effect of sorafenib in liver cancer cells. Biochem Pharmacol. 2023 May;211:115538.